nach oben

Erschienen in:

15.02.2018 | Observational Research

Canakinumab treatment in children with familial Mediterranean fever: report from a single center

verfasst von: Fatma Yazılıtaş, Özlem Aydoğ, Sare Gülfem Özlü, Evrim Kargın Çakıcı, Tülin Güngör, Fehime Kara Eroğlu, Gökçe Gür, Mehmet Bülbül

Erschienen in: Rheumatology International | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5–10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.

Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10(3):135–147. https://doi.org/10.1038/nrrheum.2013.174 CrossRefPubMed

Sarı I, Birlik M, Kasifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheumatol 1(1):21–33CrossRefPubMedPubMedCentral

French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25–31CrossRef

The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797–807CrossRef

Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL et al (2008) The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 1 112(5):1794–1803. https://doi.org/10.1182/blood-2008-01-134932 CrossRef

Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 15(6):2095–2147 (2187)

Bozkurt Y, Demir A, Erman B, Gül A (2015) Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Comput Math Methods Med 2015:893507. https://doi.org/10.1155/2015/893507 CrossRefPubMedPubMedCentral

Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146(5):467–478. https://doi.org/10.1111/j.1365-2141.2009.07733.x CrossRefPubMedPubMedCentral

Wang DQH, Bonfrate L, de Bari O, Wang TY, Portincasa P (2014) Familial Mediterranean fever: from pathogenesis to treatment. J Genet Syndr Gene Ther 5:248. https://doi.org/10.4172/2157-7412.1000248

10.

Brough D, Rothwell NJ (2007) Caspase-1-dependent processing of pro-interleukin-1 beta is cytosolic and precedes cell death. J Cell Sci 1 120 (Pt 5):772–781CrossRef

11.

Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5):586–599CrossRefPubMed

12.

Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P (2014) Novel therapeutics for the treatment of familial mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95(1):89–97CrossRefPubMed

13.

Bilginer Y, Akpolat T, Ozen S (2011) Renal amyloidosis in children. Pediatr Nephrol 26(8):1215–1227. https://doi.org/10.1007/s00467-011-1797-x CrossRefPubMedPubMedCentral

14.

Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F et al (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheum 21(4):509–514

15.

Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicineresistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11):1545–1546CrossRefPubMedPubMedCentral

16.

Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41(2):265–271. https://doi.org/10.1016/j.semarthrit.2010.11.003 CrossRefPubMed

17.

Eroglu FK, Beşbaş N, Topaloglu R, Ozen S (2015) Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 35(10):1733–1737. https://doi.org/10.1007/s00296-015-3293-2 CrossRefPubMed

18.

Haviv R, Hashkes PJ (2016) Canakinumab investigated for treating familial Mediterranean fever. Expert Opin Biol Ther 16(11):1425–1434CrossRefPubMed

19.

Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K (2011) The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and long standing destructive arthritis. Ann Rheum Dis 70(7):1347–1348. https://doi.org/10.1136/ard.2010.146878 CrossRefPubMed

20.

Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 35(2):441–446. https://doi.org/10.1007/s10067-014-2772-2 CrossRefPubMed

21.

Sozeri B, Gulez N, Ergin M, Serdaroglu E (2016) The experience of canakinumab in renal amyloidosis secondary to familial Mediterranean fever. Mol Cell Pediatr 3(1):33. https://doi.org/10.1186/s40348-016-0058-2 CrossRefPubMedPubMedCentral

22.

Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31(4):633–640. https://doi.org/10.1007/s00467-015-3249-5 CrossRefPubMed

23.

Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L et al (2015) Renal involvement in secondary amyloidosis of Muckle–Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol 34(7):1311–1316. https://doi.org/10.1007/s10067-013-2481-2 CrossRefPubMed

24.

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885CrossRefPubMed

25.

Ozen S, Kone-Paut I, Gül A (2017) Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum 47(1):115–120. https://doi.org/10.1016/j.semarthrit.2017.03.006 CrossRefPubMed

26.

Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33(4):273–282CrossRefPubMed

27.

Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A et al (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) and Turkish FMF study group. Ann Rheum Dis 73(5):897–901. https://doi.org/10.1136/annrheumdis-2013-204719 CrossRefPubMed

28.

Cakar N, Yalçinkaya F, Ozkaya N, Tekin M, Akar N, Koçak H et al (2001) Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 19(5 Suppl 24):S63–S67PubMed

29.

Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005. https://doi.org/10.1056/nejm198604173141601 CrossRefPubMed

30.

Shohat M (2000) In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, Stephens K, Amemiya A, Ledbetter N (eds) GeneReviews® (internet), 1993–2017. University of Washington, Seattle (updated 15 Dec 2016)

31.

Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E et al (2010) Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 37(1):182–189. https://doi.org/10.3899/jrheum.090273 CrossRefPubMed

32.

Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690 CrossRefPubMed

33.

Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73(2):462–469. https://doi.org/10.1136/annrheumdis-2012-202774 CrossRefPubMed

34.

Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29(4 Suppl 67):S87–S90PubMed

35.

Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 29(2):209–210. https://doi.org/10.1007/s10067-009-1279-8 CrossRefPubMed

36.

Başaran Ö, Uncu N, Çelikel BA, Taktak A, Gür G, Cakar N (2015) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 25(4):621–624. https://doi.org/10.3109/14397595.2014.987437 CrossRefPubMed

37.

Ozdogan H, Ugurlu S (2017) Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 13(5):393–404. https://doi.org/10.1080/1744666X.2017.1313116 CrossRefPubMed

38.

Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L et al (2014) Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study (Hoboken, NJ). Arthritis Rheumatol (Hoboken NJ) 66(11):3241–3243. https://doi.org/10.1002/art.38777 CrossRef

39.

Ozkan S, Atas B (2017) Canakinumab treatment in four children with colchicine resistant familial mediterranean fever. J Pak Med Assoc 67(6):945–947PubMed

40.

Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 17:243. https://doi.org/10.1186/s13075-015-0765-4

41.

Salehzadeh F, Yasrebi O, Hosseini Khotbesara M, Hosseini Khotbesara M (2014) Idiopathic uveitis and familial Mediterranean fever: is there any relationship? Autoimmune Dis 2014:238931. https://doi.org/10.1155/2014/238931 PubMedPubMedCentral

42.

Berestizschevsky S, Weinberger D, Avisar I, Avisar R. Episcleritis associated with familial Mediterranean fever. Isr Med Assoc J 10(4):318–319

43.

Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2015) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 34(7):1293–1301. https://doi.org/10.1007/s10067-013-2443-8 CrossRefPubMed

44.

Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591. https://doi.org/10.1136/annrheumdis-2012-201383 CrossRefPubMed

45.

Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):191–197. https://doi.org/10.1007/s10067-016-3506-4 CrossRefPubMed

46.

Brambilla A, Caputo R, Cimaz R, Simonini G (2016) Canakinumab for childhood sightthreatening refractory uveitis: a case series. J Rheumatol 43(7):1445–1447. https://doi.org/10.3899/jrheum.160064 CrossRefPubMed

47.

Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H, Nishikomori R et al (2015) Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study. J Ophthalmic Inflamm Infect 5(1):34. https://doi.org/10.1186/s12348-015-0065-9 CrossRefPubMedPubMedCentral

48.

Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V et al (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. ArthritisRheum 65(2):513–518. https://doi.org/10.1002/art.37776 CrossRef

Titel: Canakinumab treatment in children with familial Mediterranean fever: report from a single center
verfasst von: Fatma Yazılıtaş
Özlem Aydoğ
Sare Gülfem Özlü
Evrim Kargın Çakıcı
Tülin Güngör
Fehime Kara Eroğlu
Gökçe Gür
Mehmet Bülbül
Publikationsdatum: 15.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 5/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-018-3993-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Canakinumab treatment in children with familial Mediterranean fever: report from a single center

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study

Frailty in end-stage hip or knee osteoarthritis: validation of the Groningen Frailty Indicator (GFI) questionnaire

Low- and high-anxious hypermobile Ehlers–Danlos syndrome patients: comparison of psychosocial and health variables

Chronic disease list conditions in patients with rheumatoid arthritis in the private healthcare sector of South Africa

Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease

Ultrasound scans and dual energy CT identify tendons as preferred anatomical location of MSU crystal depositions in gouty joints

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin